Solid Biosciences (SLDB) Registration filing summary

Company overview and business model

• Focuses on developing gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich's ataxia.

• Pipeline includes SGT-003, SGT-212, SGT-501, SGT-601, and additional assets at various development stages.

• Mission centers on improving daily lives of patients with severe genetic diseases.

Financial performance and metrics

• Raised approximately $240 million in gross proceeds from a private placement in March 2026, before fees and expenses.

• 42,780,739 shares registered for resale, including 27,807,482 shares issuable upon exercise of pre-funded warrants.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders.

• Proceeds from the private placement were received by the company; resale proceeds go to selling stockholders.